Response to cimetidine in a 1-year-old child with PFAPA syndrome

Kazuto Taniguchi1, Nobuyasu Ono2, Tatsuya Sakai1

  • 1Cho-ritsu Tara Hospital, Tara, Saga, Japan.

Insights

Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome can be managed with cimetidine to reduce febrile attacks. This may be a useful interim treatment until tonsillectomy is a safer option for children.

Area of Science:

  • Pediatrics
  • Immunology
  • Otolaryngology

Background:

  • Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome presents with recurrent febrile episodes.
  • Tonsillectomy is an established treatment, but its suitability varies with age.
  • The efficacy of cimetidine for PFAPA syndrome remains debated.

Purpose of the Study:

  • To evaluate the effectiveness of cimetidine in managing PFAPA syndrome.
  • To present case studies illustrating treatment outcomes.
  • To explore cimetidine as a potential bridge therapy before tonsillectomy.

Main Methods:

  • Case report of a 1-year-old girl treated with cimetidine.
  • Case report of a 6-year-old boy who underwent tonsillectomy.
  • Clinical observation of symptom reduction and treatment success.

Main Results:

  • Cimetidine treatment in a pediatric patient led to a reduction in febrile attacks.
  • Successful tonsillectomy was performed in an older pediatric patient.
  • Both interventions showed positive outcomes for PFAPA syndrome management.

Conclusions:

  • Cimetidine may effectively reduce febrile episodes in PFAPA syndrome.
  • This treatment can be considered until tonsillectomy is age-appropriate.
  • Further research is warranted to confirm cimetidine's role in PFAPA management.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
258
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
289
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
344
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
344
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
20
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.1K